Dapagliflozin + spironolactone

Dapagliflozin + spironolactone has been studied in 2 papers since 2026: 1 trial in people, 1 review; 2 in the past year. The newest paper, Aug 12, 2026: “Diabetes, Adiposity, and Functional Phenotypes in HFpEF: A Systematic Review of Recent Treatment-Response Evidence”.

Intervention

2 papers study it8 more mention it2 findingsUpdated

PubChemPubChemChEBIChEBI

5 new papers in 30 daysSee all 10 papers on dapagliflozin + spironolactone

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“Group C achieved a significantly greater UAER reduction compared to Group A and Group B (P < 0.05)”
Effect of dapagliflozin-spironolactone combination therapy versus monotherapy on albuminuria reduction and hyperkalemia risk in elderly patients with early type 2 diabetic nephropathy receiving high-dose RASi: A randomized controlled trialThe American journal of the medical sciences2026doi:10.1016/j.amjms.2026.05.005

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Human trial1

Studies in people

1 study gave dapagliflozin + spironolactone to people and measured what changed.

What changedDesignPeopleSource

down: Decreases urinary albumin excretion rate

down: Decreases hyperkalemia

Randomized trial72 weeks168 peopleelderlyOlder adults; on irbesartan background therapyThe American journal of the medical sciences, May 20, 2026

What did studies of dapagliflozin + spironolactone find?

2

Studies of dapagliflozin + spironolactone measured 2 outcomes: hyperkalemia and urinary albumin excretion rate.

Hyperkalemia

downin humans1

1 study
  1. Dapagliflozin + spironolactone decreases hyperkalemia in humans (on irbesartan background therapy; relative to spironolactone-associated hyperkalemia).

    “while attenuating the risk of spironolactone-associated hyperkalemia”

    Human trialon irbesartan background therapy; relative to spironolactone-associated hyperkalemia72 weeks

    Effect of dapagliflozin-spironolactone combination therapy versus monotherapy on albuminuria reduction and hyperkalemia risk in elderly patients with early type 2 diabetic nephropathy receiving high-dose RASi: A randomized controlled trial

    The American journal of the medical sciences

More on Hyperkalemia

Urinary albumin excretion rate

downin humans1

1 study
  1. Dapagliflozin + spironolactone decreases urinary albumin excretion rate in humans (on irbesartan background therapy).

    “Group C achieved a significantly greater UAER reduction compared to Group A and Group B (P < 0.05)”

    Human trialon irbesartan background therapy72 weeks

    Effect of dapagliflozin-spironolactone combination therapy versus monotherapy on albuminuria reduction and hyperkalemia risk in elderly patients with early type 2 diabetic nephropathy receiving high-dose RASi: A randomized controlled trial

    The American journal of the medical sciences

More on Urinary albumin excretion rate

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 2Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 1Oct 2026: 2Nov 2026: 28 papers in 12 months